Novel squamosamide derivative (compound FLZ) attenuates Abeta25-35-induced toxicity in SH-SY5Y cells

Acta Pharmacologica Sinica
Fang Fang, Geng-Tao Liu

Abstract

The aim of the present study was to investigate the protective effect of compound N-[2-(4-hydroxy-phenyl)-ethyl]-2-(2,5-dimethoxy-phenyl)-3-(3-methoxy-4-hydroxy-phenyl)-acrylamide (compound FLZ), a novel synthetic analogue of nature squamosamide, on Abeta25-35-induced toxicity and its active mechanism in human neuroblastoma SH-SY5Y cells. SH-SY5Y cells were pre-incubated with various concentrations of compound FLZ for 30 min and then cultivated with Abeta25-35 (25 micromol/L) for 48 h to induce neurotoxicity. Cell viability, lactate dehydrogenase (LDH) release, and the glutathione (GSH) level were determined by a biochemical analysis. The cell apoptotic ratio and intracellular reactive oxygen species (ROS) level were measured by a flow cytometry analysis. The expression of apoptosis protein (Bcl-2 and Bax) and cytochrome c release were assayed by the Western blot method. The pretreatment of SH-SY5Y cells with FLZ (1 and 10 micromol/L) markedly increased cell viability and decreased LDH release and morphological injury. Also, FLZ attenuated the Abeta25-35-induced apoptotic cell ratio, regulated the apoptosis protein (Bcl-2 and Bax) expression, and decreased the cytochrome c release from mitochondria. FLZ also significantly inhib...Continue Reading

References

Apr 10, 1992·Science·J A Hardy, G A Higgins
Jun 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·C L MastersK Beyreuther
Sep 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·D T LooC W Cotman
Mar 1, 1996·Free Radical Research·M Wiedau-PazosD E Bredesen
Aug 2, 1996·The Journal of Biological Chemistry·D J Selkoe
Oct 1, 1996·Brain Pathology·C W Cotman, J H Su
Mar 27, 1998·FEBS Letters·V P Skulachev
Jun 6, 1998·Proceedings of the National Academy of Sciences of the United States of America·J M JürgensmeierJ C Reed
Jan 5, 2000·Physiological Reviews·D G Nicholls, S L Budd
Jul 11, 2000·The European Journal of Neuroscience·S BastianettoR Quirion
Aug 8, 2001·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·J XuC Y Hsu
Apr 10, 2003·Free Radical Biology & Medicine·Jung-Hee Jang, Young-Joon Surh
Sep 23, 2003·Journal of Molecular Neuroscience : MN·Yossi Gilgun-SherkiDaniel Offen
Oct 14, 2003·Biochemical Pharmacology·Anne EckertWalter E Müller
Dec 4, 2003·Current Opinion in Cell Biology·Tomomi Kuwana, Donald D Newmeyer
Jan 28, 2004·Free Radical Biology & Medicine·Haiyan ZengBaolu Zhao
Oct 16, 2004·Journal of Pineal Research·Zheng Feng, Jun-Tian Zhang
Feb 23, 2005·Current Drug Targets. CNS and Neurological Disorders·John J Shacka, Kevin A Roth
Mar 8, 2005·Neurobiology of Aging·Antonio CherubiniLuigi Ferrucci

❮ Previous
Next ❯

Citations

Sep 28, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Xuan YeDan Zhang
Aug 20, 2009·The Journal of Biological Chemistry·Nicoletta PasquarielloMauro Maccarrone
Jan 25, 2018·Environmental Technology·Jacqueline A MalvestitiRenato F Dantas

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis